Bickling Financial Services, Inc. Editas Medicine, Inc. Transaction History

Bickling Financial Services, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 01, 2021	SELL	$39.27 - $72.94 $157,080 - $291,760	-4,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $125,160 - $226,560	4,000 New	4,000 $227,000
Q1 2021 May 12, 2021	SELL	$39.71 - $90.58 $199,741 - $455,617	-5,030 Closed	0 $0
Q4 2020 Feb 26, 2021	BUY	$27.07 - $84.35 $136,162 - $424,280	5,030 New	5,030 $353,000

246

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $92.1M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Bickling Financial Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Bickling Financial Services, Inc. with notifications on news.